The evidence for the use of selenium supplementation in cancer prevention is still inconclusive. Rataan et al suggest that the fault may lie in the design of the existing studies. At least two factors have contributed to this lack of conclusive evidence:
- the use of different compounds in the tests of selenium and cancer
- the different blood selenium levels of the study participants at baseline
As an example, Rataan et al cite the differences between the Nutritional Prevention of Cancer (NPC) trial and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). In the NPC study, the researchers used a selenium-enriched yeast supplement. This yeast formulation contained mostly selenomethionine but also contained several other selenium species including Se-methylselenocysteine. In the SELECT study, the researchers used a 100% selenomethionine supplement. It now seems clear that the chemopreventive effect of selenium that was seen in the NPC study but not seen in the SELECT study must have come from some selenium species other than selenomethionine. The most likely chemopreventive selenium species is the Se-methylselenocysteine [Rataan 2022; Marshall 2017].
